Department of Hepatobiliary Surgery, People's Hospital of Deyang City, Deyang, Sichuan, China.
Department of Pediatrics, People's Hospital of Deyang City, Deyang, Sichuan, China.
J Healthc Eng. 2022 Mar 21;2022:8223336. doi: 10.1155/2022/8223336. eCollection 2022.
The efficacy and safety of transcatheter arterial chemoembolization (TACE) are systematically evaluated in the treatment of primary liver cancer, which provides a reference for clinical practice and more in-depth research. Cochrane Library, PubMed, EMbase, CBM, CNKI, VIP, and WanFang Data, supplemented by other searches, collected all randomized controlled trials (RCT) comparing TACE combined with TACE alone for HCC. The meta-analysis, after selecting the literature, extracting data, and evaluating the methodological quality of the included studies following the inclusion criteria, was performed using RevMan 5.1 software. There was statistical difference in 3-year survival rate of TACE combined with heat treatment for advanced hepatocellular carcinoma (OR = 1.72,95%CI (1.22,2.41), =0.002, I = 0%, and = 3.12), total effective rate (OR = 1.91,95%CI (1.31,2.78), =0.0008, I = 0%, and = 3.37), quality-of-life improvement rate (OR = 2.29,95%CI (1.62,3.23), < 0.00001, I = 83%, and = 3.37), and complication rate (OR = 2.29,95%CI (1.62,3.23), < 0.00001, I = 83%, and = 3.37). Compared with TACE alone, TACE combined with hyperthermia can significantly improve the survival rate and recent efficacy of patients, improve the quality of life, and have a trend to reduce the incidence of toxicity. However, its long-term efficacy and more comprehensive safety need to be verified by more sample and high-quality RCT.
经导管动脉化疗栓塞(TACE)治疗原发性肝癌的疗效和安全性得到了系统评价,为临床实践和更深入的研究提供了参考。 Cochrane Library、PubMed、EMbase、CBM、CNKI、VIP 和万方数据等数据库进行检索,补充其他检索,收集所有比较 TACE 联合 TACE 与单纯 TACE 治疗 HCC 的随机对照试验(RCT)。根据纳入标准,对文献进行选择、数据提取和纳入研究方法学质量评价后,采用 RevMan 5.1 软件进行荟萃分析。TACE 联合热疗治疗晚期肝细胞癌的 3 年生存率(OR=1.72,95%CI(1.22,2.41), =0.002,I=0%, =3.12)、总有效率(OR=1.91,95%CI(1.31,2.78), =0.0008,I=0%, =3.37)、生活质量改善率(OR=2.29,95%CI(1.62,3.23), <0.00001,I=83%, =3.37)和并发症发生率(OR=2.29,95%CI(1.62,3.23), <0.00001,I=83%, =3.37)差异均有统计学意义。与 TACE 单独治疗相比,TACE 联合热疗可显著提高患者的生存率和近期疗效,提高生活质量,且有降低毒性发生率的趋势。但长期疗效和更全面的安全性还需要更多样本、高质量 RCT 来验证。